FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home.

Risdiplam (Evrysdi) is a liquid medicine intended for daily use that was developed by Roche subsidiary Genentech in partnership with the SMA Foundation and South Plainfield, NJ-based PTC Therapeutics (NASDAQ: PTCT).